This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Zimmermann M., Zimmermann-Kogadeeva M., Wegmann R., Goodman A.L.: Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature, 2019; 570: 462-467ZimmermannM.Zimmermann-KogadeevaM.WegmannR.GoodmanA.L.Mapping human microbiome drug metabolism by gut bacteria and their genesNature201957046246710.1038/s41586-019-1291-3Search in Google Scholar
Turnbaugh P.J., Ley R.E., Hamady M., Fraser-Liggett C.M., Knight R., Gordon J.I.: The human microbiome project. Nature, 2007; 449: 804-810TurnbaughP.J.LeyR.E.HamadyM.Fraser-LiggettC.M.KnightR.GordonJ.I.The human microbiome projectNature200744980481010.1038/nature06244Search in Google Scholar
Swanson H.I.: Drug metabolism by the host and gut microbiota: A partnership or rivalry? Drug Metab. Dispos., 2015; 43: 1499-1504SwansonH.I.Drug metabolism by the host and gut microbiota: A partnership or rivalry? Drug MetabDispos2015431499150410.1124/dmd.115.065714Search in Google Scholar
Wilson I.D., Nicholson J.K.: Gut microbiome interactions with drug metabolism, efficacy, and toxicity. Transl. Res., 2017; 179: 204222WilsonI.D.NicholsonJ.K.Gut microbiome interactions with drug metabolism, efficacy, and toxicityTransl. Res201717920422210.1016/j.trsl.2016.08.002Search in Google Scholar
Franzosa E.A., Huang K., Meadow J.F., Gevers D., Lemon K.P., Bohannan B.J., Huttenhower C.: Identifying personal microbiomes using metagenomic codes. Proc. Natl. Acad. Sci. USA, 2015; 112: E2930-E2938FranzosaE.A.HuangK.MeadowJ.F.GeversD.LemonK.P.BohannanB.J.HuttenhowerC.Identifying personal microbiomes using metagenomic codesProc. Natl. Acad. Sci. USA2015112E2930E293810.1073/pnas.1423854112Search in Google Scholar
Baker J.M., Al-Nakkash L., Herbst-Kralovetz M.M.: Estrogen-gut microbiome axis: Physiological and clinical implications. Maturitas, 2017; 103: 45-53BakerJ.M.Al-NakkashL.Herbst-KralovetzM.M.Estrogen-gut microbiome axis: Physiological and clinical implicationsMaturitas2017103455310.1016/j.maturitas.2017.06.025Search in Google Scholar
Conlon M.A., Bird A.R.: The impact of diet and lifestyle on gut microbiota and human health. Nutrients, 2015; 7: 17-44ConlonM.A.BirdA.R.The impact of diet and lifestyle on gut microbiota and human healthNutrients20157174410.3390/nu7010017Search in Google Scholar
Crovesy L., Masterson D., Rosado E.L.: Profile of the gut microbiota of adults with obesity: A systematic review. Eur. J. Clin. Nutr., 2020; 74, 1251-1262CrovesyL.MastersonD.RosadoE.L.Profile of the gut microbiota of adults with obesity: A systematic reviewEur. J. Clin. Nutr2020741251–126210.1038/s41430-020-0607-6Search in Google Scholar
Hopkins M.J., Sharp R., Macfarlane G.T.: Variation in human intestinal microbiota with age. Dig. Liver Dis., 2002; 34: S12-S18HopkinsM.J.SharpR.MacfarlaneG.T.Variation in human intestinal microbiota with ageDig. Liver Dis200234S12S1810.1016/S1590-8658(02)80157-8Search in Google Scholar
Claesson M.J., Jeffery I.B., Conde S., Power S.E., O’Connor E.M., Cusack S., Harris H.M., Coakley M., Lakshminarayanan B., O’Sullivan O. i wsp.: Gut microbiota composition correlates with diet and health in the elderly. Nature, 2012; 488: 178-184ClaessonM.J.JefferyI.B.CondeS.PowerS.E.O’ConnorE.M.CusackS.HarrisH.M.CoakleyM.LakshminarayananB.O’SullivanO. i wsp.Gut microbiota composition correlates with diet and health in the elderlyNature201248817818410.1038/nature1131922797518Search in Google Scholar
Clark R.I. Walker D.W.: Role of gut microbiota in aging-related health decline: Insights from invertebrate models. Cell Mol. Life Sci., 2018; 75: 93-101Clark R.I. Walker D.WRole of gut microbiota in aging-related health decline: Insights from invertebrate modelsCell Mol. Life Sci2018759310110.1007/s00018-017-2671-1575425629026921Search in Google Scholar
Clarke G., O’Mahony S.M., Dinan T.G., Cryan J.F.: Priming for health: Gut microbiota acquired in early life regulates physiology, brain and behaviour. Acta Paediatr., 2014; 103: 812-819ClarkeG.O’MahonyS.M.DinanT.G.CryanJ.F.Priming for health: Gut microbiota acquired in early life regulates physiology, brain and behaviourActa Paediatr201410381281910.1111/apa.1267424798884Search in Google Scholar
Dogra S., Sakwinska O., Soh S.E., Ngom-Bru C., Brück W.M., Berger B., Brüssow H., Lee Y.S., Yap F., Chong Y.S. i wsp.: Dynamics of infant gut microbiota are influenced by delivery mode and gestational duration and are associated with subsequent adiposity. mBio, 2015; 6: e02419-14DograS.SakwinskaO.SohS.E.Ngom-BruC.BrückW.M.BergerB.BrüssowH.LeeY.S.YapF.ChongY.S. i wsp.Dynamics of infant gut microbiota are influenced by delivery mode and gestational duration and are associated with subsequent adipositymBio20156e024191410.1128/mBio.02419-14432341725650398Search in Google Scholar
Brinkworth G.D., Noakes M., Clifton P.M., Bird A.R.: Comparative effects of very low-carbohydrate, high-fat and high-carbohydrate, low-fat weight-loss diets on bowel habit and faecal short-chain fatty acids and bacterial populations. Br. J. Nutr., 2009; 101: 14931502BrinkworthG.D.NoakesM.CliftonP.M.BirdA.R.Comparative effects of very low-carbohydrate, high-fat and high-carbohydrate, low-fat weight-loss diets on bowel habit and faecal short-chain fatty acids and bacterial populationsBr. J. Nutr20091011493150210.1017/S000711450809465819224658Search in Google Scholar
Ticinesi A., Milani C., Lauretani F., Nouvenne A., Mancabelli L., Lugli G.A., Turroni F., Duranti S., Mangifesta M., Viappiani A. i wsp.: Gut microbiota composition is associated with polypharmacy in elderly hospitalized patients. Sci. Rep., 2017; 7: 11102TicinesiA.MilaniC.LauretaniF.NouvenneA.MancabelliL.LugliG.A.TurroniF.DurantiS.MangifestaM.ViappianiA. i wsp.Gut microbiota composition is associated with polypharmacy in elderly hospitalized patientsSci. Rep201771110210.1038/s41598-017-10734-y559388728894183Search in Google Scholar
Stokholm J., Thorsen J., Blaser M.J., Rasmussen M.A., Hjelmsø M., Shah S., Christensen E.D., Chawes B.L., Bønnelykke K., Brix S. i wsp.: Delivery mode and gut microbial changes correlate with an increased risk of childhood asthma. Sci. Transl. Med., 2020; 12: eaax9929StokholmJ.ThorsenJ.BlaserM.J.RasmussenM.A.HjelmsøM.ShahS.ChristensenE.D.ChawesB.L.BønnelykkeK.BrixS. i wsp.Delivery mode and gut microbial changes correlate with an increased risk of childhood asthmaSci. Transl. Med202012eaax992910.1126/scitranslmed.aax992933177184Search in Google Scholar
Tropini C., Earle K.A., Huang K.C., Sonnenburg J.L.: The gut microbiome: Connecting spatial organization to function. Cell Host Microbe, 2017; 21: 433-442TropiniC.EarleK.A.HuangK.C.SonnenburgJ.L.The gut microbiome: Connecting spatial organization to functionCell Host Microbe20172143344210.1016/j.chom.2017.03.010557635928407481Search in Google Scholar
Cheng Y., Jin U.H., Allred C.D., Jayaraman A., Chapkin R.S., Safe S.: Aryl hydrocarbon receptor activity of tryptophan metabolites in young adult mouse colonocytes. Drug Metab. Dispos., 2015; 43: 1536-1543ChengY.JinU.H.AllredC.D.JayaramanA.ChapkinR.S.SafeS.Aryl hydrocarbon receptor activity of tryptophan metabolites in young adult mouse colonocytesDrug Metab. Dispos2015431536154310.1124/dmd.115.063677457667625873348Search in Google Scholar
Zelante T., Iannitti R,G., Cunha C., De Luca A., Giovannini G., Pieraccini G., Zecchi R., D’Angelo C., Massi-Benedetti C., Fallarino F.: Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity, 2013; 39: 372-385ZelanteT.IannittiR.,G.CunhaC.De LucaA.GiovanniniG.PieracciniG.ZecchiR.D’AngeloC.Massi-BenedettiC.FallarinoF.Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22Immunity20133937238510.1016/j.immuni.2013.08.00323973224Search in Google Scholar
Maranduba C.M., De Castro S.B., de Souza G.T., Rossato C., da Guia F.C., Valente M.A., Rettore J.V., Maranduba C.P., de Souza C.M., do Carmo A.M. i wsp.: Intestinal microbiota as modulators of the immune system and neuroimmune system: Impact on the host health and homeostasis. J. Immunol. Res., 2015; 2015: 931574MarandubaC.M.De CastroS.B.de SouzaG.T.RossatoC.da GuiaF.C.ValenteM.A.RettoreJ.V.MarandubaC.P.de SouzaC.M.do CarmoA.M. i wsp.Intestinal microbiota as modulators of the immune system and neuroimmune system: Impact on the host health and homeostasisJ. Immunol. Res2015201593157410.1155/2015/931574435247325759850Search in Google Scholar
Björkholm B., Bok C.M., Lundin A., Rafter J., Hibberd M.L., Pettersson S.: Intestinal microbiota regulate xenobiotic metabolism in the liver. PLoS One, 2009; 4: e6958BjörkholmB.BokC.M.LundinA.RafterJ.HibberdM.L.PetterssonS.Intestinal microbiota regulate xenobiotic metabolism in the liverPLoS One20094e695810.1371/journal.pone.0006958273498619742318Search in Google Scholar
Kaur H., Bose C., Mande S.S.: Tryptophan metabolism by gut microbiome and gut-brain-axis: An in silico analysis. Front. Neurosci., 2019; 13: 1365KaurH.BoseC.MandeS.S.Tryptophan metabolism by gut microbiome and gut-brain-axis: An in silico analysisFront. Neurosci201913136510.3389/fnins.2019.01365693023831920519Search in Google Scholar
Ridaura V., Belkaid Y.: Gut microbiota: The link to your second brain. Cell, 2015; 161: 193-194RidauraV.BelkaidY.Gut microbiota: The link to your second brainCell201516119319410.1016/j.cell.2015.03.03325860600Search in Google Scholar
Reigstad C.S., Salmonson C.E., Rainey J.F.3rd, Szurszewski J.H., Linden D.R., Sonnenburg J.L., Farrugia G., Kashyap P.C.: Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells. FASEB J., 2015; 29: 1395-1403ReigstadC.S.SalmonsonC.E.RaineyJ.F.3rdSzurszewskiJ.H.LindenD.R.SonnenburgJ.L.FarrugiaG.KashyapP.C.Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cellsFASEB J2015291395140310.1096/fj.14-259598439660425550456Search in Google Scholar
Vecsey C.G., Hawk J.D., Lattal K.M., Stein J.M., Fabian S.A., Attner M.A., Cabrera S.M., McDonough C.B., Brindle P.K., Abel T., Wood M.A.: Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB:CBP-dependent transcriptional activation. J. Neurosci. 2007; 27: 6128-6140VecseyC.G.HawkJ.D.LattalK.M.SteinJ.M.FabianS.A.AttnerM.A.CabreraS.M.McDonoughC.B.BrindleP.K.AbelT.WoodM.A.Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB:CBP-dependent transcriptional activationJ. Neurosci2007276128614010.1523/JNEUROSCI.0296-07.2007292504517553985Search in Google Scholar
Hoyles L., Snelling T., Umlai U.K., Nicholson J.K., Carding S.R., Glen R.C., McArthur S.: Microbiome-host systems interactions: Protective effects of propionate upon the blood-brain barrier. Microbiome, 2018; 6: 55HoylesL.SnellingT.UmlaiU.K.NicholsonJ.K.CardingS.R.GlenR.C.McArthurS.Microbiome-host systems interactions: Protective effects of propionate upon the blood-brain barrierMicrobiome201865510.1186/s40168-018-0439-y586345829562936Search in Google Scholar
Kelly J.R., Kennedy P.J., Cryan J.F., Dinan T.G., Clarke G., Hyland N.P.: Breaking down the barriers: The gut microbiome, intestinal permeability and stress-related psychiatric disorders. Front. Cell. Neurosci., 2015; 9: 392KellyJ.R.KennedyP.J.CryanJ.F.DinanT.G.ClarkeG.HylandN.P.Breaking down the barriers: The gut microbiome, intestinal permeability and stress-related psychiatric disordersFront. Cell. Neurosci2015939210.3389/fncel.2015.00392460432026528128Search in Google Scholar
Baothman O.A., Zamzami M.A., Taher I., Abubaker J., Abu-Farha M.: The role of gut microbiota in the development of obesity and diabetes. Lipids Health Dis., 2016; 15: 108BaothmanO.A.ZamzamiM.A.TaherI.AbubakerJ.Abu-FarhaM.The role of gut microbiota in the development of obesity and diabetesLipids Health Dis20161510810.1186/s12944-016-0278-4491270427317359Search in Google Scholar
Becker C., Neurath M.F., Wirtz S.: The intestinal microbiota in inflammatory bowel disease. ILAR J., 2015; 56: 192-204BeckerC.NeurathM.F.WirtzS.The intestinal microbiota in inflammatory bowel diseaseILAR J20155619220410.1093/ilar/ilv03026323629Search in Google Scholar
Dahmus J.D., Kotler D.L., Kastenberg D.M., Kistler C.A.: The gut microbiome and colorectal cancer: A review of bacterial pathogenesis. J. Gastrointest. Oncol., 2018; 9: 769-777DahmusJ.D.KotlerD.L.KastenbergD.M.KistlerC.A.The gut microbiome and colorectal cancer: A review of bacterial pathogenesisJ. Gastrointest. Oncol2018976977710.21037/jgo.2018.04.07608787230151274Search in Google Scholar
Kaur H., Das C., Mande S.S.: In silico analysis of putrefaction pathways in bacteria and its implication in colorectal cancer. Front. Microbiol., 2017; 8: 2166KaurH.DasC.MandeS.S.In silico analysis of putrefaction pathways in bacteria and its implication in colorectal cancerFront. Microbiol20178216610.3389/fmicb.2017.02166568200329163445Search in Google Scholar
Hughes R., Magee E.A., Bingham S.: Protein degradation in the large intestine: Relevance to colorectal cancer. Curr. Issues Intest. Microbiol., 2000; 1: 51-58HughesR.MageeE.A.BinghamS.Protein degradation in the large intestine: Relevance to colorectal cancerCurr. Issues Intest. Microbiol200015158Search in Google Scholar
Toden S., Bird A.R., Topping D.L., Conlon M.A.: Resistant starch attenuates colonic DNA damage induced by higher dietary protein in rats. Nutr. Cancer, 2005; 51: 45-51TodenS.BirdA.R.ToppingD.L.ConlonM.A.Resistant starch attenuates colonic DNA damage induced by higher dietary protein in ratsNutr. Cancer200551455110.1207/s15327914nc5101_715749629Search in Google Scholar
Shen W., Gaskins H.R., McIntosh M.K.: Influence of dietary fat on intestinal microbes, inflammation, barrier function and metabolic outcomes. J. Nutr. Biochem., 2014; 25: 270-280ShenW.GaskinsH.R.McIntoshM.K.Influence of dietary fat on intestinal microbes, inflammation, barrier function and metabolic outcomesJ. Nutr. Biochem20142527028010.1016/j.jnutbio.2013.09.00924355793Search in Google Scholar
Nakamura J., Kubota Y., Miyaoka M., Saitoh T., Mizuno F, Benno Y.: Comparison of four microbial enzymes in Clostridia and Bacteroides isolated from human feces. Microbiol. Immunol., 2002; 46: 487-490NakamuraJ.KubotaY.MiyaokaM.SaitohT.MizunoFBennoY.Comparison of four microbial enzymes in Clostridia and Bacteroides isolated from human fecesMicrobiol. Immunol20024648749010.1111/j.1348-0421.2002.tb02723.x12222935Search in Google Scholar
Pollet R.M., D’Agostino E.H., Walton W.G., Xu Y., Little M.S., Biernat K.A., Pellock S.J., Patterson L.M., Creekmore B.C., Isenberg H.N., i wsp.: An atlas of β-glucuronidases in the human intestinal microbiome. Structure, 2017; 25: 967-977PolletR.M.D’AgostinoE.H.WaltonW.G.XuY.LittleM.S.BiernatK.A.PellockS.J.PattersonL.M.CreekmoreB.C.IsenbergH.N.iwsp.An atlas of β-glucuronidases in the human intestinal microbiomeStructure20172596797710.1016/j.str.2017.05.003553329828578872Search in Google Scholar
Vila A.V., Collij V., Sanna S., Sinha T., Imhann F., Bourgonje A.R., Mujagic Z., Jonkers D.M., Masclee A.A., Fu J. i wsp.: Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nat. Commun., 2020; 11: 362VilaA.V.CollijV.SannaS.SinhaT.ImhannF.BourgonjeA.R.MujagicZ.JonkersD.M.MascleeA.A.FuJ. i wsp.Impact of commonly used drugs on the composition and metabolic function of the gut microbiotaNat. Commun20201136210.1038/s41467-019-14177-z696917031953381Search in Google Scholar
Finlayson-Trick E.C., Fischer J.A., Goldfarb D.M., Karakochuk C.D.: The effects of iron supplementation and fortification on the gut microbiota: A review. Gastrointest. Disord., 2020; 2: 327-340Finlayson-TrickE.C.FischerJ.A.GoldfarbD.M.KarakochukC.D.The effects of iron supplementation and fortification on the gut microbiota: A reviewGastrointest. Disord2020232734010.3390/gidisord2040030Search in Google Scholar
Skonieczna-Żydecka K., Łoniewski I., Misera A., Stachowska E., Maciejewska D., Marlicz W., Galling B.: Second-generation antipsychotics and metabolism alterations: A systematic review of the role of the gut microbiome. Psychopharmacology, 2019; 236: 1491-1512Skonieczna-ŻydeckaK.ŁoniewskiI.MiseraA.StachowskaE.MaciejewskaD.MarliczW.GallingB.Second-generation antipsychotics and metabolism alterations: A systematic review of the role of the gut microbiomePsychopharmacology20192361491151210.1007/s00213-018-5102-6659897130460516Search in Google Scholar
Zhang S., Chen D.C.: Facing a new challenge: The adverse effects of antibiotics on gut microbiota and host immunity. Chin. Med. J., 2019; 132: 1135-1138ZhangS.ChenD.C.Facing a new challenge: The adverse effects of antibiotics on gut microbiota and host immunityChin. Med. J20191321135113810.1097/CM9.0000000000000245651140730973451Search in Google Scholar
Ponziani F.R., Zocco M.A., D’Aversa F., Pompili M., Gasbarrini A.: Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation. World J. Gastroenterol., 2017; 23: 4491-4499PonzianiF.R.ZoccoM.A.D’AversaF.PompiliM.GasbarriniA.Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulationWorld J. Gastroenterol2017234491449910.3748/wjg.v23.i25.4491550436428740337Search in Google Scholar
Imhann F., Bonder M.J., Vila A.V., Fu J., Mujagic Z., Vork L., Tigchelaar E.F., Jankipersadsing S.A., Cenit M.C., Harmsen H.J. i wsp.: Proton pump inhibitors affect the gut microbiome. Gut, 2016; 65: 740-748ImhannF.BonderM.J.VilaA.V.FuJ.MujagicZ.VorkL.TigchelaarE.F.JankipersadsingS.A.CenitM.C.HarmsenH.J. i wsp.Proton pump inhibitors affect the gut microbiomeGut20166574074810.1136/gutjnl-2015-310376485356926657899Search in Google Scholar
Jackson M.A., Goodrich J.K., Maxan M-E., Freedberg D.E., Abrams J.A., Poole A.C., Sutter J.L., Welter D., Ley R.E., Bell J.T. i wsp.: Proton pump inhibitors alter the composition of the gut microbiota. Gut, 2016; 65: 749-756JacksonM.A.GoodrichJ.K.MaxanM-E.FreedbergD.E.AbramsJ.A.PooleA.C.SutterJ.L.WelterD.LeyR.E.BellJ.T. i wsp.Proton pump inhibitors alter the composition of the gut microbiotaGut20166574975610.1136/gutjnl-2015-310861485357426719299Search in Google Scholar
Moayyedi P., Eikelboom J.W., Bosch J., Connolly S.J., Dyal L., Shestakovska O., Leong D., Anand S.S., Störk S., Branch K.R. i wsp.: Safety of proton pump inhibitors based on a large, multiyear, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology, 2019; 157: 682-691MoayyediP.EikelboomJ.W.BoschJ.ConnollyS.J.DyalL.ShestakovskaO.LeongD.AnandS.S.StörkS.BranchK.R. i wsp.Safety of proton pump inhibitors based on a large, multiyear, randomized trial of patients receiving rivaroxaban or aspirinGastroenterology201915768269110.1053/j.gastro.2019.05.05631152740Search in Google Scholar
Yepuri G., Sukhovershin R., Nazari-Shafti T.Z., Petrascheck M., Ghebre Y.T., Cooke J.P.: Proton pump inhibitors accelerate endothelial senescence. Circ. Res., 2016; 118: e36-e42YepuriG.SukhovershinR.Nazari-ShaftiT.Z.PetrascheckM.GhebreY.T.CookeJ.P.Proton pump inhibitors accelerate endothelial senescenceCirc. Res2016118e36e4210.1161/CIRCRESAHA.116.308807490274527166251Search in Google Scholar
Forslund K., Hildebrand F., Nielsen T., Falony G., Le Chatelier E., Sunagawa S., Prifti E., Vieira-Silva S., Gudmundsdottir V., Krogh Pedersen H. i wsp.: Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature, 2015; 528: 262-266ForslundK.HildebrandF.NielsenT.FalonyG.Le ChatelierE.SunagawaS.PriftiE.Vieira-SilvaS.GudmundsdottirV.KroghPedersen H. i wsp.Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiotaNature201552826226610.1038/nature15766468109926633628Search in Google Scholar
Wu H., Esteve E., Tremaroli V., Khan M.T., Caesar R., Mannerås-Holm L., Ståhlman M., Olsson L.M., Serino M., Planas- Fèlix M. i wsp.: Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat. Med., 2017; 23: 850-858WuH.EsteveE.TremaroliV.KhanM.T.CaesarR.Mannerås-HolmL.StåhlmanM.OlssonL.M.SerinoM.Planas-Fèlix M. i wsp.Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drugNat. Med20172385085810.1038/nm.434528530702Search in Google Scholar
Vieira-Silva S., Falony G., Belda E., Nielsen T., Aron-Wisnewsky J., Chakaroun R., Forslund S., Assmann K., Valles-Colomer M., Nguyen T.T. i wsp.: Statin therapy is associated with lower prevalence of gut microbiota dysbiosis. Nature, 2020; 581: 310-315Vieira-SilvaS.FalonyG.BeldaE.NielsenT.Aron-WisnewskyJ.ChakarounR.ForslundS.AssmannK.Valles-ColomerM.NguyenT.T. i wsp.Statin therapy is associated with lower prevalence of gut microbiota dysbiosisNature202058131031510.1038/s41586-020-2269-x32433607Search in Google Scholar
Noh K., Kang Y.R., Nepal M.R., Shakya R., Kang M.J., Kang W., Lee S., Jeong H.G., Jeong T.C.: Impact of gut microbiota on drug metabolism: An update for safe and effective use of drugs. Arch. Pharm. Res., 2017; 40: 1345-1355NohK.KangY.R.NepalM.R.ShakyaR.KangM.J.KangW.LeeS.JeongH.G.JeongT.C.Impact of gut microbiota on drug metabolism: An update for safe and effective use of drugsArch. Pharm. Res2017401345135510.1007/s12272-017-0986-y29181640Search in Google Scholar
Lauschke V.M., Ingelman-Sundberg M.: Prediction of drug response and adverse drug reactions: From twin studies to Next Generation Sequencing. Eur. J. Pharm. Sci., 2019; 130: 65-77LauschkeV.M.Ingelman-SundbergM.Prediction of drug response and adverse drug reactions: From twin studies to Next Generation SequencingEur. J. Pharm. Sci2019130657710.1016/j.ejps.2019.01.02430684656Search in Google Scholar
Sharma A., Buschmann M.M., Gilbert J.A.: Pharmacomicrobiomics: The holy grail to variability in drug response? Clin. Pharmacol. Ther., 2019; 106: 317-328SharmaA.BuschmannM.M.GilbertJ.A.Pharmacomicrobiomics: The holy grail to variability in drug response? ClinPharmacol. Ther201910631732810.1002/cpt.143730937887Search in Google Scholar
Claesson M.J., Clooney A.G., O’Toole P.W.: A clinician’s guide to microbiome analysis. Nat. Rev. Gastroenterol. Hepatol., 2017; 14: 585-595ClaessonM.J.ClooneyA.G.O’TooleP.W.A clinician’s guide to microbiome analysisNat. Rev. Gastroenterol. Hepatol20171458559510.1038/nrgastro.2017.9728790452Search in Google Scholar
Davenport E.R., Sanders J.G., Song S.J., Amato K.R., Clark A.G., Knight R.: The human microbiome in evolution. BMC Biol., 2017; 15: 127DavenportE.R.SandersJ.G.SongS.J.AmatoK.R.ClarkA.G.KnightR.The human microbiome in evolutionBMC Biol20171512710.1186/s12915-017-0454-7574439429282061Search in Google Scholar
Arkhipova O.V., Akimenko V.K.: Unsaturated organic acids as terminal electron acceptors for reductase chains of anaerobic bacteria. Mikrobiologiia, 2005; 74: 725-737ArkhipovaO.V.AkimenkoV.K.Unsaturated organic acids as terminal electron acceptors for reductase chains of anaerobic bacteriaMikrobiologiia20057472573710.1007/s11021-005-0116-6Search in Google Scholar
Koppel N., Rekdal V.M., Balskus E.P.: Chemical transformation of xenobiotics by the human gut microbiota. Science, 2017; 356: 1246-1257KoppelN.RekdalV.M.BalskusE.P.Chemical transformation of xenobiotics by the human gut microbiotaScience20173561246125710.1126/science.aag2770553434128642381Search in Google Scholar
Clarke G., Sandhu K.V., Griffin B.T., Dinan T.G., Cryan J.F., Hyland N.P.: Gut reactions: Breaking down xenobiotic-microbiome interactions. Pharmacol. Rev., 2019; 71: 198-224ClarkeG.SandhuK.V.GriffinB.T.DinanT.G.CryanJ.F.HylandN.P.Gut reactions: Breaking down xenobiotic-microbiome interactionsPharmacol. Rev20197119822410.1124/pr.118.01576830890566Search in Google Scholar
Gopalakrishnan V., Spencer C.N., Nezi L., Reuben A., Andrews M.C., Karpinets T.V., Prieto P.A., Vicente D., Hoffman K., Wei S.C. i wsp.: Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science, 2018; 359: 97-103GopalakrishnanV.SpencerC.N.NeziL.ReubenA.AndrewsM.C.KarpinetsT.V.PrietoP.A.VicenteD.HoffmanK.WeiS.C. i wsp.Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patientsScience20183599710310.1126/science.aan4236582796629097493Search in Google Scholar
Routy B., Le Chatelier E., Derosa L., Duong C.P., Alou M.T., Daillère R., Fluckiger A., Messaoudene M., Rauber C., Roberti M.P. i wsp.: Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science, 2018; 359: 91-97RoutyB.Le ChatelierE.DerosaL.DuongC.P.AlouM.T.DaillèreR.FluckigerA.MessaoudeneM.RauberC.RobertiM.P. i wsp.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumorsScience2018359919710.1126/science.aan370629097494Search in Google Scholar
Hubbard T.D., Murray I.A., Perdew G.H.: Indole and tryptophan metabolism: Endogenous and dietary routes to Ah receptor activation. Drug Metab. Dispos., 2015; 43: 1522-1535HubbardT.D.MurrayI.A.PerdewG.H.Indole and tryptophan metabolism: Endogenous and dietary routes to Ah receptor activationDrug Metab. Dispos2015431522153510.1124/dmd.115.064246457667326041783Search in Google Scholar
Jin U.H., Lee S.O., Sridharan G., Lee K., Davidson L.A., Jayaraman A., Chapkin R.S., Alaniz R., Safe S.: Microbiome-derived tryptophan metabolites and their aryl hydrocarbon receptor-dependent agonist and antagonist activities. Mol. Pharmacol., 2014; 85: 777-788JinU.H.LeeS.O.SridharanG.LeeK.DavidsonL.A.JayaramanA.ChapkinR.S.AlanizR.SafeS.Microbiome-derived tryptophan metabolites and their aryl hydrocarbon receptor-dependent agonist and antagonist activitiesMol. Pharmacol20148577778810.1124/mol.113.091165399001424563545Search in Google Scholar
Venkatesh M., Mukherjee S., Wang H., Li H., Sun K., Benechet A.P., Qiu Z., Maher L., Redinbo M.R., Phillips R.S. i wsp.: Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and Toll-like receptor 4. Immunity, 2014; 41: 296-310VenkateshM.MukherjeeS.WangH.LiH.SunK.BenechetA.P.QiuZ.MaherL.RedinboM.R.PhillipsR.S. i wsp.Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and Toll-like receptor 4Immunity20144129631010.1016/j.immuni.2014.06.014414210525065623Search in Google Scholar
Wallace B.D., Redinbo M.R.: Xenobiotic-sensing nuclear receptors involved in drug metabolism: A structural perspective. Drug Metab. Rev., 2013; 45: 79-100WallaceB.D.RedinboM.R.Xenobiotic-sensing nuclear receptors involved in drug metabolism: A structural perspectiveDrug Metab. Rev2013457910010.3109/03602532.2012.740049487869423210723Search in Google Scholar
Lee S.H., An J.H., Lee H.J., Jung B.H.: Evaluation of pharmacokinetic differences of acetaminophen in pseudo germ-free rats. Biopharm. Drug Dispos., 2012; 33: 292-303LeeS.H.AnJ.H.LeeH.J.JungB.H.Evaluation of pharmacokinetic differences of acetaminophen in pseudo germ-free ratsBiopharm. Drug Dispos20123329230310.1002/bdd.179922806334Search in Google Scholar
Li H., He J., Jia W.: The influence of gut microbiota on drug metabolism and toxicity. Expert Opin. Drug. Metab. Toxicol., 2016; 12: 31-40LiH.HeJ.JiaW.The influence of gut microbiota on drug metabolism and toxicityExpert Opin. Drug. Metab. Toxicol201612314010.1517/17425255.2016.1121234568318126569070Search in Google Scholar
Possamai L.A., McPhail M.J., Khamri W., Wu B., Concas D., Harrison M., Williams R., Cox R.D., Cox I.J., Anstee Q.M., Thursz M.R.: The role of intestinal microbiota in murine models of acetaminophen-induced hepatotoxicity. Liver Int., 2015; 35: 764-773PossamaiL.A.McPhailM.J.KhamriW.WuB.ConcasD.HarrisonM.WilliamsR.CoxR.D.CoxI.J.AnsteeQ.M.ThurszM.R.The role of intestinal microbiota in murine models of acetaminophen-induced hepatotoxicityLiver Int20153576477310.1111/liv.12689587351625244648Search in Google Scholar
Sousa T., Yadav V., Zann V., Borde A., Abrahamsson B., Basit A.W.: On the colonic bacterial metabolism of azo-bonded prodrugs of 5-aminosalicylic acid. J. Pharm. Sci., 2014; 103: 3171-3175SousaT.YadavV.ZannV.BordeA.AbrahamssonB.BasitA.W.On the colonic bacterial metabolism of azo-bonded prodrugs of 5-aminosalicylic acidJ. Pharm. Sci20141033171317510.1002/jps.2410325091594Search in Google Scholar
Deloménie C., Fouix S., Longuemaux S., Brahimi N., Bizet C., Picard B., Denamur E., Dupret J.M.: Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: Evidence for highly selective acetylation of 5-aminosalicylic acid. J. Bacteriol., 2001; 183: 3417-3427DeloménieC.FouixS.LonguemauxS.BrahimiN.BizetC.PicardB.DenamurE.DupretJ.M.Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: Evidence for highly selective acetylation of 5-aminosalicylic acidJ. Bacteriol20011833417342710.1128/JB.183.11.3417-3427.20019964011344150Search in Google Scholar
Kaddurah-Daouk R., Baillie R.A., Zhu H., Zeng Z.B., Wiest M.M, Nguyen U.T., Wojnoonski K., Watkins S.M, Trupp M., Krauss R.M.: Enteric microbiome metabolites correlate with response to simvastatin treatment. PLoS One, 2011; 6: e 25482Kaddurah-DaoukR.BaillieR.A.ZhuH.ZengZ.B.WiestM.MNguyenU.T.WojnoonskiK.WatkinsS.MTruppM.KraussR.M.Enteric microbiome metabolites correlate with response to simvastatin treatmentPLoS One20116e 2548210.1371/journal.pone.0025482319275222022402Search in Google Scholar
Yoo D.H., Kim I.S., Van Le T.K., Jung I.H., Yoo H.H., Kim D.H.: Gut microbiota-mediated drug interactions between lovastatin and antibiotics. Drug Metab. Dispos., 2014; 42: 1508-1513YooD.H.KimI.S.VanLe T.K.JungI.H.YooH.H.KimD.H.Gut microbiota-mediated drug interactions between lovastatin and antibioticsDrug Metab. Dispos2014421508151310.1124/dmd.114.05835424947972Search in Google Scholar
Viaud S., Flament C., Zoubir M., Pautier P., LeCesne A., Ribrag V., Soria J.C., Marty V., Vielh P., Robert C. i wsp.: Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res. 2011; 71: 661-665ViaudS.FlamentC.ZoubirM.PautierP.LeCesneA.RibragV.SoriaJ.C.MartyV.VielhP.RobertC. i wsp.Cyclophosphamide induces differentiation of Th17 cells in cancer patientsCancer Res20117166166510.1158/0008-5472.CAN-10-125921148486Search in Google Scholar
Viaud S., Saccheri F., Mignot G., Yamazaki T., Daillère R., Hannani D., Enot D.P., Pfirschke C., Engblom C., Pittet M.J. i wsp.: The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science, 2013; 342: 971-976ViaudS.SaccheriF.MignotG.YamazakiT.DaillèreR.HannaniD.EnotD.P.PfirschkeC.EngblomC.PittetM.J. i wsp.The intestinal microbiota modulates the anticancer immune effects of cyclophosphamideScience201334297197610.1126/science.1240537404894724264990Search in Google Scholar
Roberts A.B., Wallace B.D., Venkatesh M.K., Mani S., Redinbo M.R.: Molecular insights into microbial β-glucuronidase inhibition to abrogate CPT-11 toxicity. Mol. Pharmacol., 2013; 84: 208-217RobertsA.B.WallaceB.D.VenkateshM.K.ManiS.RedinboM.R.Molecular insights into microbial β-glucuronidase inhibition to abrogate CPT-11 toxicityMol. Pharmacol20138420821710.1124/mol.113.085852371632623690068Search in Google Scholar
Saitta K.S., Zhang C., Lee K.K., Fujimoto K., Redinbo M.R., Boelsterli U.A.: Bacterial β-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: Mode of action and pharmacokinetics. Xenobiotica, 2014; 44: 28-35SaittaK.S.ZhangC.LeeK.K.FujimotoK.RedinboM.R.BoelsterliU.A.Bacterial β-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: Mode of action and pharmacokineticsXenobiotica201444283510.3109/00498254.2013.811314397261723829165Search in Google Scholar
Choi M.S., Yu J.S., Yoo H.H., Kim D.H.: The role of gut microbiota in the pharmacokinetics of antihypertensive drugs. Pharmacol. Res., 2018; 130: 164-171ChoiM.S.YuJ.S.YooH.H.KimD.H.The role of gut microbiota in the pharmacokinetics of antihypertensive drugsPharmacol. Res201813016417110.1016/j.phrs.2018.01.01929391236Search in Google Scholar
Haiser H.J., Gootenberg D.B., Chatman K., Sirasani G., Balskus E.P., Turnbaugh P.J.: Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science, 2013; 341: 295-298HaiserH.J.GootenbergD.B.ChatmanK.SirasaniG.BalskusE.P.TurnbaughP.J.Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lentaScience201334129529810.1126/science.1235872373635523869020Search in Google Scholar
Haiser H.J., Seim K.L., Balskus E.P., Turnbaugh P.J.: Mechanistic insight into digoxin inactivation by Eggerthella lenta augments our understanding of its pharmacokinetics. Gut Microbes, 2014; 5: 233-238HaiserH.J.SeimK.L.BalskusE.P.TurnbaughP.J.Mechanistic insight into digoxin inactivation by Eggerthella lenta augments our understanding of its pharmacokineticsGut Microbes2014523323810.4161/gmic.27915406385024637603Search in Google Scholar
Kumar K., Jaiswal S.K., Dhoke G.V., Srivastava G.N., Sharma A.K., Sharma V.K.: Mechanistic and structural insight into promiscuity based metabolism of cardiac drug digoxin by gut microbial enzyme. J. Cell. Biochem., 2018; 119: 5287-5296KumarK.JaiswalS.K.DhokeG.V.SrivastavaG.N.SharmaA.K.SharmaV.K.Mechanistic and structural insight into promiscuity based metabolism of cardiac drug digoxin by gut microbial enzymeJ. Cell. Biochem20181195287529610.1002/jcb.2663829274283Search in Google Scholar
Hashim H., Azmin S., Razlan H., Yahya N.W., Tan H.J., Manaf M.R., Ibrahim N.M.: Eradication of Helicobacter pylori infection improves levodopa action, clinical symptoms and quality of life in patients with Parkinson’s disease. PLoS One, 2014; 9: e112330HashimH.AzminS.RazlanH.YahyaN.W.TanH.J.ManafM.R.IbrahimN.M.Eradication of Helicobacter pylori infection improves levodopa action, clinical symptoms and quality of life in patients with Parkinson’s diseasePLoS One20149e11233010.1371/journal.pone.0112330423904925411976Search in Google Scholar
Matuskova Z., Anzenbacher P., Vecera R., Siller M., TlaskalovaHogenova H., Strojil J., Anzenbacherova E.: Effect of Lactobacillus casei on the pharmacokinetics of amiodarone in male Wistar rats. Eur. J. Drug Metab. Pharmacokinet., 2017; 42: 29-36MatuskovaZ.AnzenbacherP.VeceraR.SillerM.TlaskalovaHogenovaH.StrojilJ.AnzenbacherovaE.Effect of Lactobacillus casei on the pharmacokinetics of amiodarone in male Wistar ratsEur. J. Drug Metab. Pharmacokinet201742293610.1007/s13318-015-0315-026797809Search in Google Scholar
Nakayama H., Kinouchi T., Kataoka K., Akimoto S., Matsuda Y., Ohnishi Y.: Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil. Pharmacogenetics, 1997; 7: 35-43NakayamaH.KinouchiT.KataokaK.AkimotoS.MatsudaY.OhnishiY.Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracilPharmacogenetics19977354310.1097/00008571-199702000-000059110360Search in Google Scholar
Okuda H., Ogura K., Kato A., Takubo H., Watabe T.: A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. J. Pharmacol. Exp. Ther., 1998; 287: 791-799OkudaH.OguraK.KatoA.TakuboH.WatabeT.A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugsJ. Pharmacol. Exp. Ther1998287791799Search in Google Scholar
Poteres E., Hubert N., Poludasu S., Brigando G., Moore J., Keeler K., Isabelli A., Ibay I.C., Alt L., Pytynia M. i wsp.: Selective regional alteration of the gut microbiota by diet and antibiotics. Front. Physiol., 2020; 11: 797PoteresE.HubertN.PoludasuS.BrigandoG.MooreJ.KeelerK.IsabelliA.IbayI.C.AltL.PytyniaM. i wsp.Selective regional alteration of the gut microbiota by diet and antibioticsFront. Physiol20201179710.3389/fphys.2020.00797735840032733284Search in Google Scholar
Stojančević M., Bojić G., Salami H.A., Mikov M.: The influence of intestinal tract and probiotics on the fate of orally administered drugs. Curr. Issues Mol. Biol., 2014; 16: 55-68StojančevićM.BojićG.SalamiH.A.MikovM.The influence of intestinal tract and probiotics on the fate of orally administered drugsCurr. Issues Mol. Biol2014165568Search in Google Scholar
Zeevi D., Korem T., Zmora N., Israeli D., Rothschild D., Weinberger A., Ben-Yacov O., Lador D., Avnit-Sagi T., Lotan-Pompan M. i wsp.: Personalized nutrition by prediction of glycemic responses. Cell, 2015; 163: 1079-1094ZeeviD.KoremT.ZmoraN.IsraeliD.RothschildD.WeinbergerA.Ben-YacovO.LadorD.Avnit-SagiT.Lotan-PompanM. i wsp.Personalized nutrition by prediction of glycemic responsesCell20151631079109410.1016/j.cell.2015.11.00126590418Search in Google Scholar
Wallace B.D., Roberts A.B., Pollet R.M., Ingle J.D., Biernat K.A., Pellock S.J., Venkatesh M.K., Guthrie L., O’Neal S.K., Robinson S.J. i wsp.: Structure and inhibition of microbiome β-glucuronidases essential to the alleviation of cancer drug toxicity. Chem. Biol., 2015; 22: 1238-1249WallaceB.D.RobertsA.B.PolletR.M.IngleJ.D.BiernatK.A.PellockS.J.VenkateshM.K.GuthrieL.O’NealS.K.RobinsonS.J. i wsp.Structure and inhibition of microbiome β-glucuronidases essential to the alleviation of cancer drug toxicityChem. Biol2015221238124910.1016/j.chembiol.2015.08.005457590826364932Search in Google Scholar